Sorcero, the AI-powered intelligence platform transforming life sciences, has raised $42.5 million in Series B funding led by NewSpring Growth, with participation from Leawood Venture Capital and Blu Ventures.
The round brings the company’s total funding to $59 million and positions Sorcero to accelerate global expansion across medical affairs, safety, scientific communications, and medical devices.
The platform already serves one-third of the top 30 global pharma companies, helping them unlock actionable insights from vast medical data sets. Sorcero customers report up to a 92% boost in productivity for generating scientific evidence and can produce published manuscripts and value dossiers two to five months faster than traditional methods.
Sorcero’s suite—Medical, SciComms, Safety, and Medtech—combines life sciences–specific AI, the largest medically enriched data pool in the industry, and a platform built to meet strict regulatory and privacy standards. Its AI agents analyze more than 263 million publications, 1.3 billion citations, and hundreds of global data sources, offering healthcare professionals (HCPs) precise, real-time insights for evidence-based engagement.
“Our vision is to create a unified intelligence platform for the precision medicine era,” said CEO and co-founder Dipanwita Das. “By putting evidence and physicians’ needs at the center, we help life sciences teams generate insights faster, target the right patients, and improve outcomes—all while accelerating therapy adoption.”
As precision medicine and specialty drugs dominate new approvals, adoption remains a major bottleneck. 76% of new products fail to secure half of payor coverage within six months, and 70% of HCPs report pharma reps don’t understand their needs. Sorcero aims to close that gap by transforming fragmented global data into actionable intelligence for targeted, compliant engagement.
Investors see strong potential for Sorcero to redefine AI in life sciences. “Sorcero is uniquely positioned to become the vertical AI platform precision medicine demands,” said Hart Callahan, NewSpring General Partner. Life sciences software veteran Dan Goldsmith added: “Sorcero delivers measurable value at scale—accelerating evidence generation and transforming how therapies reach patients.”
